The Library

Browse by Warwick Author

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Official Date | Item Type | Funder | No Grouping
Jump to: 2020 | 2019 | 2018 | 2016 | 2011 | 2006
Number of items: 6.

2020

Earl, Helena, Hiller, Louise, Vallier, Anne-Laure, Loi, Shrushma, McAdam, Karen, Hughes-Davies, Luke, Rea, Daniel, Howe, Donna L., Raynes, Kerry, Higgins, Helen B. et al.
(2020) Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer : the PERSEPHONE non-inferiority RCT. Health Technology Assessment, 24 (40). pp. 1-190. doi:10.3310/hta24400 ISSN 1366-5278.

2019

Earl, Helena M., Hiller, Louise, Vallier, Anne-Laure, Loi, Shrushma, McAdam, Karen, Hughes-Davies, Luke, Harnett, Adrian N, Ah-See, Mei-Lin, Simcock, Richard, Rea, Daniel et al.
(2019) 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE) : 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. The Lancet, 393 (10191). pp. 2599-2612. doi:10.1016/S0140-6736(19)30650-6 ISSN 0140-6736.

2018

Hiller, Louise, Dunn, Janet A., Loi, Shrushma, Vallier, Anne-Laure, Howe, Donna L., Cameron, David A., Miles, David, Wardley, Andrew M. and Earl, Helena M. (2018) Adjuvant trastuzumab duration trials in HER2 positive breast cancer : what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results. BMC Cancer, 18 . 391. doi:10.1186/s12885-018-4307-8 ISSN 1471-2407.

2016

Earl, Helena M, Vallier, Anne-Laure, Dunn, Janet A., Loi, Shrushma, Ogburn, Emma, McAdam, Karen, Hughes-Davies, Luke, Harnett, Adrian, Abraham, Jean, Wardley, Andrew, Cameron, David A, Miles, David, Gounaris, Ioannis, Plummer, Chris and Hiller, Louise (2016) Trastuzumab-associated cardiac events in the Persephone trial. British Journal of Cancer, 115 (12). pp. 1462-1470. doi:10.1038/bjc.2016.357 ISSN 0007-0920.

2011

Hiller, Louise, Dunn, Janet A., Higgins, Helen B., Ogburn-Storey, Emma, Loi, Shrushma, Vallier, Anne-Laure and Earl, Helena M. (2011) Optimising patient recall of adverse events over prolonged time periods. Trials, Vol.12 (Suppl.1). A74. doi:10.1186/1745-6215-12-S1-A74 ISSN 1745-6215.

2006

Poole, C. J., Hiller, Louise, Howard, H. C., Loi, Shrushma, Dunn, Janet A., Canney, P., Wardley, A. M., Crown, J. P., Coleman, R. E., Verrill, M. W., Ellis, P. A., Leonard, R. C., Spooner, David A. and Earl, Helena M. (2006) Tolerability of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy in the randomized phase III tAnGo trial for invasive higher risk early stage breast cancer. In: 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, DEC 14-17, 2006. Published in: BREAST CANCER RESEARCH AND TREATMENT, 100 (Suppl. 1). S114-S114. ISSN 0167-6806.

This list was generated on Mon Jun 5 20:47:38 2023 BST.